Acadia Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Acadia Pharmaceuticals Inc in the third quarter 2026?
Acadia Pharmaceuticals Inc achieved a return on average equity (ROE) of 28.03 % in its third quarter 2026, this is above ACAD's average return on equity of -35.45%.
Acadia Pharmaceuticals Inc shareholder's equity over the 12 months ending in its third quarter 2026 are valued at $1,292 million

ROE fell compared to the second quarter 2026, despite the net income growth of 69.92% from the second quarter 2026.

Within the Major Pharmaceutical Preparations industry 25 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2026 from 229 to 301.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Equity Change	51.26 %	58.88 %	63.1 %	67.49 %	-
Y / Y Net Income Change	-25.43 %	18.13 %	-80.84 %	90.32 %	119.07 %
Net Income (TTM) in Millions	362	380	376	391	261
Return On Equity (TTM)	28.03 %	32.39 %	35.65 %	41.9 %	32.27 %
ACAD's Total Ranking	# 301	# 229	# 0	# 256	#
Equity (TTM) in Millions	1,387	1,307	1,248	1,227	917
Seq. Equity Change	6.19 %	4.69 %	1.68 %	33.81 %	11.54 %
Seq. Net Income Change	69.92 %	766.1 %	-98.67 %	281.13 %	169.18 %

Back to ACAD Management Effectiveness >> ACAD's 5 Years Annual ROE >> Compare ACAD ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 26
Sector	# 59
Overall	# 301

Return On Equity Statistics
High	Average	Low
41.9 %	-35.45 %	-108.46 %
(Dec 31 2025)		(Sep 30 2012)

ACAD Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	1,227	733	432	400	541
Y / Y Equity Change	67.49 %	69.72 %	7.83 %	-25.97 %	-13.73 %
Net Income in Millions	391	226	-61	-216	-168
Y / Y Net Income Change	72.66 %	-	-	-	-
Return On Equity	31.86 %	30.9 %	-14.19 %	-53.94 %	-31.04 %

Back to ACAD Management Effectiveness >> ACAD's 5 Years Annual ROE >> Compare ACAD ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 31.86 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ACAD's' Return on Equity at Yahoo Finance
ACAD's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ACAD's Competitors
Subscribers only: Roe for Acadia Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for ACAD's Customers

Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector	ROE
Rigel Pharmaceuticals Inc	73.94 %
Idexx Laboratories Inc	71.18 %
Tenet Healthcare Corp	57.13 %
Aurinia Pharmaceuticals Inc	51.92 %
Nurix Therapeutics Inc	49.34 %
Carlisle Companies Incorporated	44.18 %
Bristol myers Squibb Company	43.83 %
Zevra Therapeutics Inc	38.02 %
Dexcom Inc	36.56 %
Rallybio Corporation	36.35 %
Caredx Inc	34.08 %
Chemed Corporation	32.10 %
Illumina Inc	31.45 %
Transmedics Group Inc	28.74 %
Acadia Pharmaceuticals Inc	28.03 %
Pro dex Inc	26.91 %
Sotera Health Company	26.41 %
Pacs Group Inc	25.65 %
Standard Biotools Inc	25.58 %
Resmed Inc	25.50 %
Bioventus Inc	24.60 %
Encompass Health Corporation	24.08 %
Iradimed Corporation	23.90 %
Corcept Therapeutics Inc	22.88 %
Msa Safety Inc	21.79 %
Lantheus Holdings Inc	21.72 %
Iqvia Holdings Inc	21.40 %
Denali Therapeutics Inc	21.40 %
West Pharmaceutical Services Inc	21.08 %
Brightspring Health Services Inc	20.31 %

Date modified: 2026-11-09T06:44:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.